 New Online FAT now available
                      
                        New Online FAT now available
                        We adjusted our organization to COVID-19 emergency to continue…
 Quality Management System
                      
                        Quality Management System
                        The Challenge Consumers have high demands when it comes…
 SMEPAC test passed with HC dedusters and metal checks
                      
                        SMEPAC test passed with HC dedusters and metal checks
                        Dedusters and Metal Checks Standardized Measurement of Equipment Particulate…
 Pharma Technology in the Top 10 “Trends Gazelles 2020”
                      
                        Pharma Technology in the Top 10 “Trends Gazelles 2020”
                        «I am proud to say that we have the…
 Maintaining Press Cleanliness with External Lubrication: What is the Key?
                      
                        Maintaining Press Cleanliness with External Lubrication: What is the Key?
                        Benefits of External Lubrication External lubrication has proven to…
 Exhibition | COPHEX South Korea – APR 22 to APR 25, 2025
                      
                        Exhibition | COPHEX South Korea – APR 22 to APR 25, 2025
                        Join us at COPHEX in South Korea – April…
 
                  
                  
                    We are delighted to announce that Pharma Technology supports the 2024 QC Barometer initiated by Biopharmark, showcasing our commitment to advancing Quality Control in OSD drug product manufacturing.
With the current emergence of continuous manufacturing and the associated introduction of innovative technologies, there is a need for a different, improved approach to Quality Control. Within this context, the 2024 QC Barometer has been initiated to better understand how companies are responding to current industry challenges and reacting to new trends, such as Process Analytical Technologies (PATs), paving the way for real-time release testing.
After the data collection period, study results will be anonymously published in a final report due in June 2024. It will enable companies from the OSD pharmaceutical industry to position themselves against other industry players and ultimately make better-informed decisions about their Quality Control Strategy.
If you are active in the Quality Control for OSD drug product manufacturing, we invite you to participate in this global survey. As an industry expert, your insights are valuable to shape the future of Quality Control in our industry.
We are convinced that, together, we can drive innovation and progress.